|
|||||
|
|
Plasma matrix metalloproteinase 7, CC-chemokine ligand 18, and periostin as markers for pulmonary sarcoidosis |
|
| Institution: | 1. Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan;2. Shinjuku Tsurukame Clinic, Tokyo, Japan;3. Department of Laboratory Medicine, Toho University School of Medicine, Tokyo, Japan;4. Shino-test Co. Ltd, Tokyo, Japan;5. Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan;6. Department of Advanced and Integrated Interstitial Lung Disease Research, School of Medicine, Toho University, Tokyo, Japan;1. Department of Rheumatology, Oslo University Hospital, Oslo, Norway;2. Research Institute for Internal Medicine, Oslo University Hospital, Oslo, Norway;3. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;4. Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway;5. Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway;6. Institute of Clinical Medicine, University of Oslo, Oslo, Norway;1. School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan;2. Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan;3. School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan;4. Department of Institute Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;1. Key Laboratory of Ministry of Education for Conservation and Utilization of Special Biological Resources in the Western, and College of Life Science, Ningxia University, Yinchuan, Ningxia 750021, China;2. Department of Anatomy and Cell Biology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA;3. Department of Pulmonary and Critical Care Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China;4. Institute of Human Stem Cell Research, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China;5. Department of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China;6. Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China |
| Abstract: | BackgroundSome patients with sarcoidosis experience worsening of pulmonary lesions. However, no biomarker has been identified that reflects pulmonary disease status in sarcoidosis. We investigated the usefulness of potential markers of pulmonary fibrosis in patients with sarcoidosis.MethodsPlasma matrix metalloproteinase 7 (MMP-7), CC-chemokine ligand 18 (CCL-18), and periostin levels were evaluated in 60 patients with sarcoidosis and 30 healthy controls; bronchoalveolar lavage fluid levels were analyzed in 22 patients with sarcoidosis. To determine the usefulness of these markers, we explored potential correlations between these markers and sarcoidosis clinical characteristics.ResultsPlasma MMP-7, CCL-18, and periostin concentrations were significantly higher in patients with sarcoidosis than those in healthy controls. MMP-7 concentrations in plasma and bronchoalveolar lavage fluid were higher in patients with sarcoidosis with parenchymal infiltration than in those without lung lesions. Moreover, MMP-7 concentration was negatively correlated with pulmonary function.ConclusionAmong these novel biomarkers, MMP-7 most precisely reflected pulmonary sarcoidosis disease status and thus, might be useful for diagnosing and evaluating sarcoidosis, particularly in patients with pulmonary parenchymal lesions. |
| Keywords: | Matrix metalloproteinase 7 CC-Chemokine ligand 18 Periostin Pulmonary fibrosis Sarcoidosis ACE"} {"#name":"keyword" "$":{"id":"kwrd0040"} "$$":[{"#name":"text" "_":"angiotensin-converting enzyme sIL-2R"} {"#name":"keyword" "$":{"id":"kwrd0050"} "$$":[{"#name":"text" "_":"soluble interleukin 2 receptor KL-6"} {"#name":"keyword" "$":{"id":"kwrd0060"} "$$":[{"#name":"text" "_":"Krebs von den Lungen-6 IPF"} {"#name":"keyword" "$":{"id":"kwrd0070"} "$$":[{"#name":"text" "_":"idiopathic pulmonary fibrosis MMP-7"} {"#name":"keyword" "$":{"id":"kwrd0080"} "$$":[{"#name":"text" "_":"matrix metalloproteinase 7 CCL-18"} {"#name":"keyword" "$":{"id":"kwrd0090"} "$$":[{"#name":"text" "_":"CC-chemokine ligand 18 BALF"} {"#name":"keyword" "$":{"id":"kwrd0100"} "$$":[{"#name":"text" "_":"bronchoalveolar lavage fluid ELISA"} {"#name":"keyword" "$":{"id":"kwrd0110"} "$$":[{"#name":"text" "_":"enzyme-linked immunosorbent assay ROC"} {"#name":"keyword" "$":{"id":"kwrd0120"} "$$":[{"#name":"text" "_":"receiver operating characteristic FVC"} {"#name":"keyword" "$":{"id":"kwrd0130"} "$$":[{"#name":"text" "_":"forced vital capacity %FVC"} {"#name":"keyword" "$":{"id":"kwrd0140"} "$$":[{"#name":"text" "_":"percent predicted forced vital capacity MMPs"} {"#name":"keyword" "$":{"id":"kwrd0150"} "$$":[{"#name":"text" "_":"matrix metalloproteinases MMP-8"} {"#name":"keyword" "$":{"id":"kwrd0160"} "$$":[{"#name":"text" "_":"matrix metalloproteinase 8 MMP-9"} {"#name":"keyword" "$":{"id":"kwrd0170"} "$$":[{"#name":"text" "_":"matrix metalloproteinase 9 TNF-α"} {"#name":"keyword" "$":{"id":"kwrd0180"} "$$":[{"#name":"text" "_":"tumor necrosis factor α IFN-γ"} {"#name":"keyword" "$":{"id":"kwrd0190"} "$$":[{"#name":"text" "_":"interferon-γ TGF-β"} {"#name":"keyword" "$":{"id":"kwrd0200"} "$$":[{"#name":"text" "_":"transforming growth factor β IL-4"} {"#name":"keyword" "$":{"id":"kwrd0210"} "$$":[{"#name":"text" "_":"interleukin 4 IL-13"} {"#name":"keyword" "$":{"id":"kwrd0220"} "$$":[{"#name":"text" "_":"interleukin 13 |
| 本文献已被 ScienceDirect 等数据库收录！ | |